Command Palette

Search for a command to run...

Clinical Trials · NCT01149421

A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes

CompletedPhase 2Dulaglutide (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
Eli Lilly and Company
Enrollment
755
Start date
Jun 2010
Locations
76 sites, 8 countries
Primary endpoint
Change From Baseline to 16 Weeks in Mean 24-hour Systolic Blood Pressure (SBP)
View Dulaglutide compound reference